Immunologic and Inflammatory Reactions to Exogenous Stem Cells Implications for Experimental Studies and Clinical Trials for Myocardial Repair by Buja, L. Maximilian & Vela, Deborah
W
e
b
m
s
i
m
a
e
d
v
t
d
e
x
m
t
d
F
L
t
o
r
a
Journal of the American College of Cardiology Vol. 56, No. 21, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PImmunologic and Inflammatory Reactions
to Exogenous Stem Cells
Implications for Experimental Studies
and Clinical Trials for Myocardial Repair
L. Maximilian Buja, MD, Deborah Vela, MD
Houston, Texas
Intense research is under way to determine the optimal stem cell type and regimen for repairing diseased myo-
cardium. Although initial studies in humans focused on the use of homologous stem cells, allogeneic or xenoge-
neic stem cells have been studied extensively in experimental work. Clinical trials with allogeneic stem cells are
now under way, an approach based on the premise that stem cells and precursor cells are characterized as be-
ing immunotolerant. However, evidence indicates that stem cells may gain immune potency in vivo, especially
when delivered to inflamed tissue, such as acutely infarcted myocardium. Histopathologic studies show the pres-
ence of a lymphohistiocytic inflammatory reaction at the sites of delivery of allogeneic stem cells, a response
that is exaggerated with the use of xenogeneic stem cells. The immune-mediated inflammatory reaction to allo-
geneic and xenogeneic stem cells may elicit a spectrum of effects, ranging from beneficial (e.g., increased para-
crine activity) to detrimental (e.g., accelerated damage and removal of stem cells). Although the issue of
immune-mediated inflammatory responses to non-self stem cells requires further evaluation, non-self stem cells
should not be considered as immunologically inert or exclusively immunosuppressive in vivo. (J Am Coll
Cardiol 2010;56:1693–700) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.041l
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with the advent of regenerative medicine, considerable
ffort has been directed at overcoming the fundamental
iology of the mammalian myocardium to achieve not only
yocardial repair, but also myocardial regeneration in re-
ponse to injury. Results of initial experimental studies
ndicated the beneficial effects of stem cells on damaged
yocardium, and human clinical trials quickly followed
fter the publication of observations suggesting that exog-
nously administered stem cells may contribute to myocar-
ial regeneration (1–3).
In initial clinical trials, autologous stem cells were har-
ested from the bone marrow of the patient undergoing cell
herapy, processed in culture, and delivered to the myocar-
ium by various methods (1–6). However, in most of the
xperimental studies preceding these trials, allogeneic or
enogeneic stem cells were used in animal models of
yocardial injury, and immunologic reactions were con-
rolled by using various strategies (i.e., immunosuppressive
rugs or immunodeficient animals). Moreover, the under-
rom the Cardiovascular Pathology Research Laboratory, Texas Heart Institute at St.
uke’s Episcopal Hospital, Houston, Texas; Department of Pathology and Labora-
ory Medicine, University of Texas Medical School, Houston, Texas; and University
f Texas Health Science Center at Houston, Houston, Texas. The authors have
eported that they have no relationships to disclose.w
Manuscript received April 29, 2010; revised manuscript received June 17, 2010,
ccepted June 21, 2010.ying assumption was that stem cells exhibit immune toler-
nce and low immunogenicity. This putative immunotoler-
nce of certain types of stem cells has led to the emergence
f new clinical programs involving the administration of
roprietary allogeneic human stem cells to patients with
eart disease. Given these considerations, the goal of this
ommentary is to increase awareness of the immunologic
nd inflammatory reactions to exogenously administered
tem cells—a topic that has received only limited attention.
mmunology of Stem Cells
n exogenous cell delivered to a host is expected to
ncounter some form of host resistance. Recognition of
oreign antigen initiates an immune response that involves
he activation and proliferation of specific immune cells. At
he heart of this response is a set of specific antigens called
ajor histocompatibility complex (MHC) antigens that are
xpressed on each cell of the body. The MHC antigens were
riginally recognized for their role in initiating T-cell
esponses that lead to the rejection of transplanted tissue. By
inding to foreign antigens, MHC molecules form com-
lexes that are recognized by specific T cells, thus initiating
cascade of events to identify and eliminate foreign invad-
rs. The MHC class I antigens are traditionally associated
ith the activation of CD8 cytotoxic T lymphocytes,
hereas MHC class II antigens are recognized by CD4 T
e
t
s
t
r
s
c
E
b
(
u
E
t
h
b
m
f
T
T
i
m
a
a
r
t
i
i
p
E
t
F
u
i
e
M
i
1694 Buja and Vela JACC Vol. 56, No. 21, 2010
Immunogenicity of Stem Cells November 16, 2010:1693–700lymphocytes. However, many
stem cells express no or only low
levels of MHC antigens and have
been considered to be immuno-
privileged, or lacking in the abil-
ity to induce an immune re-
sponse. In fact, embryonic stem
cells (ESCs) and mesenchymal
stem cells (MSCs) have been
presented as the prototype of the
immunoprivileged cell for cell
transplantation studies (7,8).
As shown in Figure 1, stem
and precursor cells exhibit a
spectrum of immunologic prop-
rties, and a slowly increasing body of literature has begun
o question the immunomodulatory and immunoprivileged
tatus of various stem cells (7,9). Given the importance of
he immune status of these cells in cell therapy, we will
eview the experimental evidence for the immunoprivileged
tatus of ESCs and MSCs and present recent evidence that
ontradicts this assumption.
SCs. Undifferentiated ESCs are characterized by the
asic traits of self-renewal, clonogenicity, and pluripotency
for differentiation into multiple cell types). Our current
nderstanding of the immunoprivileged status of human
Abbreviations
and Acronyms
ESC  embryonic stem cell
HSC  hematopoetic stem
cell
iPS  induced pluripotent
stem
MHC  major
histocompatibility complex
MSC  mesenchymal stem
cell
SCID  severe combined
immunodeficiency
Figure 1 Immunologic Properties of Stem Cells
Naive embryonic stem cells and mesenchymal stem cells function to modulate an
mediated interactions with various populations of lymphocytes (B cells, T helper ce
phages. Stem cells also respond to perturbations of the host by proliferation and
cells are exposed to several host factors leading to their activation. In the process
and manifested by up-regulaton of major histocompatibility complex (MHC) class I
through stimulation-responsive alternative gene splicing and unconventional antige
the selection of autoantigens and self-tumor antigens. However, if the stem cells
and inflammatory responses by the host. Adapted from Yang (8). IL  interleukin;SCs is based on in vitro and in vivo xenogeneic transplan-
ation studies (7). These studies have collectively shown that
uman ESCs express low levels of MHC class I antigens
ut do not express MHC class II antigens or costimulatory
olecules (10–12). Furthermore, human ESCs have been
ound to evade recognition by natural killer cells and inhibit
-cell–induced stimulation by antigen-presenting cells.
hese studies have also shown that human ESCs do not
nduce an inflammatory response, or presumably, an im-
une response upon injection into immunocompetent mice
nd are, thus, candidates for immunomodulation and toler-
nce induction (7). In regenerative studies, ESCs have been
eported to have salutary effects on organ repair, including
he heart (13–16).
However, some studies contradict the idea of ESC
mmunoprivilege and suggest that ESCs are associated with
mmune rejection and teratogenicity (7–9,17–19). Trans-
lantation of undifferentiated allogeneic murine and human
SCs into mouse hearts has led to the formation of cardiac
eratomas in immunodeficient animals (18,19) (Fig. 2).
urthermore, treatment of immunocompetent animals with
ndifferentiated murine and human ESCs has resulted in
mmunologic rejection and intense inflammation after sev-
ral weeks and the up-regulation of class I and class II
HC molecules (18–23) (Fig. 2). In a comparative exper-
ment, mouse ESCs were injected into the injured myocar-
pen the native and acquired immune responses of the host through cytokine-
totoxic T cells, and natural killer [NK] cells) and dendritic cells and macro-
ntiation, which may result in tissue repair and regeneration. Concomitantly, stem
phenotype and functional properties of the stem cells are changed, as mediated
molecules, costimulation factors, and untolerized conventional antigen epitopes
e consequence is that the stem cells undergo stimulation-responsive splicing for
n-self (allogeneic or xenogeneic), they also become subject to targeted immune
interferon; TNF  tumor necrosis factor.d dam
lls, cy
differe
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November 16, 2010:1693–700 Immunogenicity of Stem Cellsium of syngeneic, allogeneic, and severe combined immu-
odeficient (SCID) mouse recipients (22). In allogeneic
ice, ESCs triggered an intense cellular inflammatory
esponse consisting of T lymphocytes (CD3) and den-
ritic cells (CD11c), as well as a humoral response. How-
ver, fewer CD3 T cells were elicited in the syngeneic
roup, and no CD3 T cells were elicited in the SCID
ice. Immunologic reactions and lymphocytic infiltration
ave also been observed after the transplantation of neural
tem cells derived from ESCs (24). These observations
ndicate that up-regulation of MHC expression occurs
hen ESCs are used to treat conditions associated with
ngoing inflammation (8). This becomes of particular con-
ideration in the cardiac field as inflammation and immune
ells play a prominent role in the early phases of myocardial
nfarction (see section “Stem Cells, Immunogenicity, and
he Infarcted Heart”).
SCs. MSCs have been described as having a range of
mmunologic traits from immunoprivilege and immunotol-
rance to immunosuppression, all supported by appropriate
n vitro studies (25–35). Adult MSCs derived from the bone
arrow and other sources have been reported to express
ewer antigens and are considered to be immunotolerant
hen delivered to allorecipients (29,31–34). Unlike most
llogeneic cells, MSCs generally do not generate a T-cell
roliferative response in an in-vitro mixed lymphocyte
eaction. In addition, cocultivation of cells with MSCs
educes the reaction to other cell types and immune-
timulating molecules, leading to speculation that MSCs
ay have a local anti-inflammatory effect in vivo (29,32).
SCs have also been reported as capable of bimodal
nti-inflammatory and immune-enhancing functions, con-
erring immune plasticity in these cells (25,33,34).
The ability of MSCs to suppress immune responses,
Syngeneic Embryonic Stem Cells
Allogeneic Embryonic Stem Cells
Stem Cells
Stem Cells
Teratom
Teratom
invadin
Figure 2 Undifferentiated ESCs Implanted Into the Myocardium
Host reactions to undifferentiated embryonic stem cells (ESCs) implanted into the
ferentiated stem cells proliferate and form teratomas. In allogeneic recipients, the
occurs, leading to an intense, targeted inflammatory reaction resulting in destructiowever, has not always held true in in-vivo studies (36–42). in a mouse model, Badillo et al. (40) showed that the
ntroduction of allogeneic MSCs into an immunologically
ompetent mouse elicits both a cellular and humoral host
mmune response and does not induce tolerance. In a similar
tudy, Poncelet et al. (42) found that allogeneic MSCs,
hen injected subcutaneously or into ischemic myocardium
n pigs, induced both a cellular and humoral response
n vivo, despite demonstrating that these cells did not elicit
proliferative T-cell response in vitro. Zangi et al. (39) used
irect imaging to examine the survival of luciferase-labeled
SCs transplanted into allogeneic mouse hearts. Although
SCs survived longer than did fibroblasts, MSC survival
as significantly shorter in allogeneic recipients than in
yngeneic mice, immune-deficient Balb-nude mice, or
onobese diabetic-SCID mice. By using T-cell antigen
eceptor transgenic mouse recipients, Zangi et al. (39)
emonstrated that MSCs may induce memory against
llogeneic MHC class I and MHC class II molecules in
D8 and CD4 T cells. Similarly, Nauta et al. (36)
howed that the injection of allogeneic donor MSCs in
aïve mice induced a memory T-cell response. Others have
eported that allogeneic MSCs were not effective against
raft-versus-host disease because of loss of their immuno-
uppressive effects in vivo (37,38).
tem Cells, Immunogenicity,
nd the Infarcted Heart
lthough often overlooked, innate and adaptive immune
echanisms contribute in an important way to the natural
istory of acute myocardial infarction (2,43). Myocardial
nfarction leads to an intense inflammatory cell influx within
he myocardium and the activation of local and systemic
mmune signaling pathways. Thus, stem cells are delivered
Cardiomyocyte
Component
ocytes
Immune rejection
with minimal
residual teratoma
rdium of syngeneic and allogeneic recipients. In syngeneic recipients, the undif-
initially proliferate to form teratomas, but at the same time, an immune reaction
he teratomas and rejection of the ESCs.a
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Immunogenicity of Stem Cells November 16, 2010:1693–700yocardial infarction, which some investigators consider as
trigger for the up-regulation of stem cell MHC expression
44). Moreover, stem cells themselves can produce various
mmunomodulatory signaling factors, including both proin-
ammatory and anti-inflammatory molecules (33,34).
The effects of exogenously administered stem cells and
recursor cells on the evolution of myocardial infarction
ave been studied in mouse and rat models (1,2,13,19,22,45–48).
n most of these studies, stem cells were delivered to
yngeneic mice or rats, or xenogeneic stem cells (including
hose from humans) were used in severely immunosup-
ressed mice or rats, such as nude or SCID mice. Both
pproaches have been designed to minimize immunologic
nd inflammatory reactions against stem cells. The benefits
f stem cell therapy have varied widely, ranging from
inimal to substantial effects on myocardial regeneration
nd repair. Of note, the inflammatory response to exog-
nously delivered stem cells has been reported in several
odent models (18–23,36–39,47–49); in 1 study, promi-
ent pathologic calcification was reported (45).
In cell therapy studies in dogs and swine, autologous
one-marrow–derived precursor cells have been shown to
mprove cardiac function, with minimal effects on the extent
f myocardial scarring and no evidence of either transdif-
erentiation or development of an immune response (50–53).
n experimental settings, allogeneic (in dogs [54], swine
55–57], and sheep [58–60]) or xenogeneic (in various
nimal models [61–66]) cells have been used more fre-
uently than autologous stem cells. In these models, the
utcome on myocardial infarction and repair has been
imilar to that seen with autologous stem cells. Specifically,
ell therapy has had beneficial effects on cardiac function,
ometimes in association with increased vascularity, but
ith little evidence of myocardial regeneration (2).
In most reports, little emphasis has been placed on
otential inflammatory or immunologic aspects of these
odels, and detailed histopathologic studies are often lack-
ng. However, critical review of the literature indicates that
ymphohistiocytic inflammatory infiltrates are directed at
oci of non-self stem cells. In a dog model of myocardial
nfarction, we observed lymphohistiocytic infiltrates in re-
ationship to administered allogeneic dog stem cells (54).
imilar findings have been described in swine and sheep
odels (56,58). Immunocytochemical studies in dogs have
hown that the cells infiltrating at cell injection sites stained
ositively for T cells (CD3) and macrophages (54). The
esidual MSCs showed no evidence of transdifferentiation
r proliferation (Ki 67). These observations support the
oncept that allogeneic stem cells develop increased immu-
ogenicity in vivo (Fig. 3). In a xenogeneic model reported
y Kim et al. (65), CD3 T cells and macrophages were
ound at the sites of stem cell delivery. In our experience
ith a similar xenogeneic model, sites of stem cell implan-
ation showed evidence of a very florid lymphohistiocytic
nfiltrate with a granulomatous component, characterized by
he presence of multinucleated giant cells (66) (Fig. 3). This nesponse developed in spite of immunosuppressive therapy
ith cyclosporine.
The findings described in the preceding text may affect
he retention of stem cells delivered into the myocardium.
n a rat model, Yasuda et al. (67) examined the retention of
ale smooth muscle cells in the female normal and infarcted
yocardium and found that only 50% of the transplanted
ells remained in the area after 1 h, with a progressive
ecrease in cell survival thereafter. At 1 and 4 weeks after
ell transplantation, about half the number of live trans-
lanted cells was retained in infarcted myocardium com-
ared with normal myocardium; the mean number of live
ells in the infarcted myocardium was 9% of the original
ose at 4 weeks. Although the decrease in cell retention in
he normal myocardium points to a baseline wash-out effect,
hese findings are also consistent with other observations
egarding the negative effect of the inflammatory milieu of
he infarcted myocardium on the fate of injected stem cells,
n effect that may be accelerated by an immune reaction (2).
n a mouse myocardial infarction model, administration of
ither bone marrow cell extract or bone marrow cells
esulted in a similar modest improvement in ejection frac-
ion (68). Although bone marrow cells were identified in the
yocardium by a prominent green fluorescence protein
ignal at 1 day, the fluorescent signal in the myocardium was
inimal by 25 days. The investigators (68) postulated that
ntact stem cells may not be necessary for a functional effect
nd that death of implanted cells may initiate a major
omponent of the benefit. The low retention rates de-
cribed in these studies may result from a combination of
tem cell death and wash-out of viable cells. In vivo
maging techniques hold promise for providing dynamic
nformation regarding the fate of exogenously administered
tem cells (69).
pproaches to Circumvent the Immune Response
everal strategies have been identified to control the im-
une and inflammatory responses targeted to non-self,
ctivated stem cells. However, given the complexity of the
ystem, experimental approaches are still under way. Several
trategies have been previously reviewed in detail (8,9,29).
dministration of naive, nonactivated MSCs has been
eneficial in controlling graft versus host disease. However,
tudies described in this review (36–42) indicate that
hronic exposure of non-self MSCs to an inflamed tissue is
ikely to lead to their activation and elicitation of a targeted
mmune response.
The use of immunosuppressants such as cyclosporine and
ycophenolate acid seems to achieve only a suboptimal
ffect in dampening the immune response in the setting of
llogeneic stem cell delivery, particularly in large-animal
odels. In a recent study, Poncelet et al. (70) showed that
he addition of a short course of tacrolimus may overcome
he immune response to intracardiac-transplanted alloge-
eic MSCs, while also preserving cell viability.
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November 16, 2010:1693–700 Immunogenicity of Stem CellsAs discussed in the preceding text, undifferentiated hu-
an ESCs produce teratomas in immunodeficient animals
nd trigger an intense inflammatory and immunologic
eaction in immunocompetent animals. In a new approach
esigned to overcome these limitations, ESCs have been
riven toward cardiomyocyte differentiation in vitro and
hen delivered as myocytic precursor cells in animal models
f cardiac injury (71). Thus, these committed cells most
ikely develop an intermediate level of immunogenicity
71). However, long-term studies showed that the effects
f these committed cells on myocardial recovery were not
ustained (72).
A new technology—induced pluripotent stem (iPS)
ells—is under intense investigation and may provide an
nnovative way to help circumvent the immune response.
his approach involves genetically reprogramming adult
omatic cells from various body sites to resemble ESCs (73).
hese dedifferentiated cells share similar morphology, gene
Autologous or Syngeneic Adult Stem Cells
Allogeneic Adult Stem Cells
Xenogeneic Adult Stem Cells
Legend
Secreted mediators, pa
?  Transdifferentiation  
?  Fusion plus mitosis   
— lymphocyte / macrophage
— multinucleated giant cell
— adult stem cell — cytok
— cytok
Figure 3 Host Reactions to Adult Stem Cells Implanted Into th
Syngeneic, Allogeneic, and Xenogeneic Conditions
Adult stem cells implanted into myocardium of autologous or syngeneic recipients
paracrine effects, leading to the proliferation of native blood vessels (angiogenesis
myocardial regeneration through transdifferentiation into new cardiomyocytes and
subsequent mitosis that produces new cells. However, major remuscularization of
thermore, stem cells injected into allogeneic recipients induce a targeted lymphoh
destruction of the stem cells. This reaction is exaggerated in the xenogeneic setti
species.xpression profiles, and differentiation potential with ESCs. the forced differentiation of iPS cells to a cardiomyocyte
ineage has been demonstrated (74). Using patient-derived
PS cells has the obvious ethical advantage over ESCs and
he theoretical benefit of avoiding the immune response
enerated with an allogeneic approach. However, other
ssues such as cell longevity and cancer development may be
f concern with the use of iPS cells.
linical Implications
he full range of implications and effects of the host
esponse to allogeneic and xenogeneic stem cells requires
urther examination. Although definitive conclusions can-
ot be reached, some evidence-based speculation can be
ade. It is possible that inflammatory cells contribute
hemical mediators to the paracrine effects triggered by the
tem cells, or the inflammatory and immunologic reactions
ay lead to the destruction of stem cells and the blunting of
e effects (angiogenesis, etc.)
ew cardiomyocyte, ? new vessels (vasculogenesis)
ew cardiomyocyte, ? new vessels
 mediators from stem cells
 mediators from inflammatory cells
?  Altered stem cell effects
ocardium Under Autologous,
ndergo some proliferation and secrete chemical mediators that contribute to
effects on cardiomyocyte function. Transplanted stem cells may result in limited
ood vessels (vasculogenesis) and/or by fusion with existing myocardial cells and
yocardium by implanted stem cells has yet to be consistently demonstrated. Fur-
tic inflammatory reaction, which likely leads to significant and accelerated
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Immunogenicity of Stem Cells November 16, 2010:1693–700In considering the implications of experimental studies
or clinical application, species variability should be consid-
red. Human MSCs and ESCs may have lower immuno-
enicity in vivo than cells from other species. Clinical
rograms involving the administration of proprietary allo-
eneic human MSCs to patients with heart disease are
nder way (75,76). The launching of such programs has
een based almost exclusively on the initial presumption of
he immunotolerance of allogeneic stem cells. To date,
dverse effects or safety issues associated with the use of
llogeneic MSCs have not been reported in clinical trials
32,75–77), although cellular and humoral responses in the
yocardium have not been well studied.
Because of untoward consequences of human gene
herapy trials, concerns have been raised regarding clin-
cal trials with stem cells, particularly human ESCs, given
hat information derived from experimental work is not
omprehensive (78,79). The important considerations
nclude oncogenicity and immunogenicity. The latter
ssues relate to the possibility that donor cells/tissue may
ventually express human leukocyte antigens that would
ctivate immunologic and inflammatory responses, lead-
ng to uncertain outcomes.
onclusions
onsiderable interest has developed in the clinical appli-
ations of ESCs and MSCs, mostly due to their immu-
oprivileged status. This protected status is now being
rought into question. Naïve stem cells appear to display
mmunomodulatory properties in vitro; however, the
ffect of transplantation itself, as well as delivery to a
ostile environment, can trigger increased immunogenic-
ty in these cells.
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